MedPath
EMA Approval

Zyprexa Velotab

N05AH03

olanzapine

Psycholeptics

olanzapine

SchizophreniaBipolar Disorder

Basic Information

EMA regulatory identification and product classification information

EMA Identifiers

ATC CodeN05AH03
EMA European Classification

Overview Summary

Comprehensive product overview and regulatory summary

This is a summary of the European public assessment report (EPAR) for Zyprexa Velotab. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zyprexa Velotab.

Authorisations (1)

EMEA/H/C/000287

CHEPLAPHARM Registration GmbH,Weilerstr. 5e,79540 Lörrach,Germany

Authorised

February 3, 2000

Active Substances (1)

olanzapine

Documents (12)

Zyprexa Velotab : EPAR - Scientific Discussion

October 20, 2005

INITIAL_MARKETING_AUTHORISATION_DOCUMENTS

Zyprexa Velotab : EPAR - Summary for the public

June 11, 2009

OVERVIEW_DOCUMENT

Zyprexa Velotab-H-C-287-P45-30 : EPAR - Assessment Report

October 10, 2012

CHANGES_SINCE_INITIAL_AUTHORISATION

Zyprexa Velotab-H-C-287-WS-485 : EPAR - Assessment Report

June 25, 2014

CHANGES_SINCE_INITIAL_AUTHORISATION

Zyprexa Velotab : EPAR - Procedural steps taken before authorisation

October 20, 2005

INITIAL_MARKETING_AUTHORISATION_DOCUMENTS

Zyprexa Velotab : EPAR - Scientific Discussion

October 20, 2005

CHANGES_SINCE_INITIAL_AUTHORISATION

Zyprexa Velotab : EPAR - Procedural steps taken and scientific information after authorisation

August 19, 2009

CHANGES_SINCE_INITIAL_AUTHORISATION

Zyprexa Velotab : EPAR - Product Information

August 19, 2009

DRUG_PRODUCT_INFORMATION

Zyprexa Velotab : EPAR - Procedural steps taken before authorisation

October 20, 2005

CHANGES_SINCE_INITIAL_AUTHORISATION

Zyprexa Velotab : EPAR - All Authorised presentations

May 2, 2007

AUTHORISED_PRESENTATIONS

Zyprexa Velotab : EPAR - Steps taken after authorisation when a cutoff date has been used

October 20, 2005

CHANGES_SINCE_INITIAL_AUTHORISATION

Zyprexa Velotab-H-C-PSUSA-00010540-201903 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

March 12, 2020

CHANGES_SINCE_INITIAL_AUTHORISATION

Overview Q&A (9)

Question

What is Zyprexa Velotab?

Answer

Zyprexa Velotab is a medicine that contains the active substance olanzapine. It is available as yellow, round ‘orodispersible’ tablets (5, 10, 15 and 20 mg). Orodispersible tablets are tablets that dissolve in the mouth.

Question

How is Zyprexa Velotab used?

Answer

The recommended starting dose of Zyprexa Velotab depends on the disease being treated: 10 mg per

day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day. The dose is adjusted according to how well the patient responds to and tolerates the treatment. The usual dose range is between 5 and 20 mg per day. The orodispersible tablets are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing. Patients over 65 years of age and patients who have reduced liver or kidney function may need a lower starting dose of 5 mg per day.

Question

How does Zyprexa Velotab work?

Answer

The active substance in Zyprexa Velotab, olanzapine, is an antipsychotic medicine. It is known as an ‘atypical’ antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. Its exact mechanism of action is unknown, but it attaches to several different receptors on the surface of nerve cells in the brain. This disrupts signals transmitted between brain cells by ‘neurotransmitters’, chemicals that allow nerve cells to communicate with each other. It is thought that olanzapine’s beneficial effect is due to it blocking receptors for the neurotransmitters 5?hydroxytrypamine (also called serotonin) and dopamine. Since these neurotransmitters are involved in schizophrenia and in bipolar disorder, olanzapine helps to normalise the activity of the brain, reducing the symptoms of these diseases.

Question

How has Zyprexa Velotab been studied?

Answer

Zyprexa Velotab contains the same active substance as another medicine called Zyprexa that has been authorised in the European Union (EU) since 1996. Because of this, the studies done with Zyprexa were used to support the use of Zyprexa Velotab. Three studies were also carried to show that, when taken by mouth, the two medicines produce equivalent levels of olanzapine in the blood.

Question

What benefit has Zyprexa Velotab shown during the studies?

Answer

Like Zyprexa, Zyprexa Velotab was more effective at improving symptoms than placebo (a dummy treatment). Zyprexa Velotab was as effective as the medicines that it was compared with for the treatment of adults with schizophrenia, the treatment of moderate to severe manic episodes in adults, and the prevention of recurrence in adults with bipolar disorder.

Question

Other information about Zyprexa Velotab

Answer

The European Commission granted a marketing authorisation valid throughout the European Union for Zyprexa Velotab on 3 February 2000.

For more information about treatment with Zyprexa Velotab, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Question

Why has Zyprexa Velotab been approved?

Answer

The CHMP decided that Zyprexa Velotab’s benefits are greater than its risks and recommended that Zyprexa Velotab be given marketing authorisation.

Question

What is the risk associated with Zyprexa Velotab?

Answer

The most common side effects with Zyprexa Velotab (seen in more than 1 patient in 10) are somnolence (sleepiness), weight gain, orthostatic hypotension (sudden drop in blood pressure on standing up) and raised levels of prolactin (a hormone). For the full list of all side effects reported with Zyprexa Velotab, see the package leaflet.

Zyprexa Velotab must not be used in people who are hypersensitive (allergic) to olanzapine or any of the other ingredients. It must also not be used in patients at risk of narrow-angle glaucoma (raised pressure inside the eye).

Question

What is Zyprexa Velotab used for?

Answer

Zyprexa Velotab is used to treat adults with schizophrenia. Schizophrenia is a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). Zyprexa Velotab is also effective in maintaining improvement in patients who have responded to an initial course of treatment.

Zyprexa Velotab is also used to treat moderate to severe manic episodes (extremely high mood) in adults. It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness causing alternating periods of high mood and depression) who have responded to an initial course of treatment.

The medicine can only be obtained with a prescription.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Zyprexa Velotab - EMA Approval | MedPath